J
Jonas Hannestad
Researcher at Yale University
Publications - 58
Citations - 3909
Jonas Hannestad is an academic researcher from Yale University. The author has contributed to research in topics: Trk receptor & Receptor. The author has an hindex of 30, co-authored 56 publications receiving 3446 citations. Previous affiliations of Jonas Hannestad include University of California, Los Angeles & UCB.
Papers
More filters
Journal ArticleDOI
The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis
TL;DR: Overall, while pharmacological antidepressant treatment reduced depressive symptoms, it did not reduce serum levels of TNFα, but antidepressant treatment did reduce levels of IL-1β and possibly those ofIL-6, which are consistent with the possibility that inflammatory cytokines contribute to depressive symptoms and that antidepressants block the effects ofinflammatory cytokines on the brain.
Journal ArticleDOI
Inflammation, glutamate, and glia in depression: a literature review.
TL;DR: An overview of how inflammation and glutamate dysfunction contribute to the pathophysiology of depression is provided and microglia activated by excess inflammation, astroglial loss, and inappropriate glutamate receptor activation ultimately disrupt the delicate balance of neuroprotective versus neurotoxic effects in the brain.
Journal ArticleDOI
Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis.
Michael H. Bloch,Jonas Hannestad +1 more
TL;DR: A meta-analysis of randomized, placebo-controlled trials of omega-3 fatty acid (FA) treatment of major depressive disorder (MDD) in order to determine efficacy and to examine sources of heterogeneity between trials demonstrated significant heterogeneity and publication bias.
Journal ArticleDOI
Neurotrophins and the immune system
TL;DR: Results from studies to date support the idea that neurotrophins may regulate some immune functions, and play an important role in the development of the thymus and in the survival of thymocytes.
Journal ArticleDOI
Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivo.
Jonas Hannestad,Jean-Dominique Gallezot,Beata Planeta-Wilson,Shu-fei Lin,Wendol Williams,Christopher H. van Dyck,Robert T. Malison,Richard E. Carson,Yu-Shin Ding +8 more
TL;DR: It is demonstrated that oral methylphenidate significantly occupies NET at clinically relevant doses, suggesting the potential relevance of NET inhibition in the therapeutic effects ofmethylphenidate in attention-deficit/hyperactivity disorder.